https://www.siliconvalley.com/2021/09/20/covid-19-vaccine-for-5-to-11-year-olds-is-safe-and-shows-robust-antibody-response-pfizer-says/

In a highly anticipated announcement, Pfizer said on Monday a Phase 2/3 trial showed its Covid-19 vaccine was safe and generated a “robust” antibody response in children ages 5 to 11.

These are the first such results released for this age group for a US Covid-19 vaccine, and the data has not yet been peer-reviewed or published. Pfizer said it plans to submit to the US Food and Drug Administration for emergency use authorization soon.